Vitagerpavak - medicine for the prevention of herpes virus 1 and 2 types.
Release form and composition
The drug is made in the form of a lyophilisate to prepare a solution for intradermal administration. One dose of Vitagerpavac (0.2 ml) contains specific antigens of the herpes simplex virus 1 and 2 types.
Auxiliary components of the drug are gelatin, sucrose, gentamicin sulfate, formaldehyde.
Externally, the lyophilisate is an amorphous mass with a pinkish tinge.
Indications for use
According to the instructions, Vitagerpavak is designed to prevent herpes simplex virus and prevent its recurrence. Vaccination is used to activate cellular immunity, cleanse and restore the body.
Doctors recommend Vitagerpavakom vaccination following categories of patients:
- In chronic course of herpes infection (with relapses three or more times a year);
- Older people (over 60-65 years old);
- HIV-infected stage 1 and 2 before the manifestation of active symptoms of AIDS.
According to the instructions, Vitagerpavak is contraindicated in the following cases:
- The presence of cancer;
- Herpes infection in the acute phase (vaccination should be given no earlier than after 5 days after the disappearance of clinical symptoms, and with ophthalmic herpes - no earlier than one month later);
- The presence of an allergic reaction to gentamicin or antibacterial drugs of the aminoglycoside group;
- Exacerbation of chronic diseases;
- Acute diseases of any etiology. Vaccination can be carried out no earlier than one month after recovery;
Dosing and Administration
Vaccination with Vitagerpavac is performed only in specialized institutions (dispensary, clinic, hospital) under the supervision of medical personnel. Before immunization, the patient must undergo a thorough medical examination with a mandatory measurement of body temperature.
The Vitagerpavac vaccine is injected intracutaneously on the inner surface of the forearm.
Before using Vitagerpavac, one vial of lyophilisate should be dissolved in 0.3 ml of sterile water for injection. To this end, a syringe with a recruited solvent is introduced into the vial, and the resulting mass is shaken until a uniform consistency is obtained.
A single dose of the solution is 0.2 ml. In case of herpes infection with damage to the skin and mucous membranes, it is recommended to undergo a course of vaccinations consisting of 5 shots, which are carried out at weekly intervals.
In the presence of a complicated infection with recurrences occurring once in 1-3 months, it is recommended to observe breaks of 10 days.
Six months later, another vaccination course consisting of 5 injections is performed.
The use of Vitagerpavac in most cases is well tolerated by patients, side effects are rare. In some cases, vaccination can cause the development of local and general reactions.
Local reactions to the introduction of Vitagerpavac expressed in hyperemia of the skin, most often during the first days after vaccination. Along with swelling, redness and a burning sensation may occur at the injection site.
General reactions to the introduction of Vitagerpavac expressed in a slight increase in body temperature and general weakness of the body. As a rule, these reactions pass independently and do not require additional treatment.
If significant local or general reactions have occurred as a result of Vitagerpavac, further vaccination should be discontinued and should be referred to a medical institution. Further vaccination can be continued only after the complete disappearance of all local or general reactions.
Ready-to-use Vitagerpavac solution is a slightly opalescent pink liquid.
If the drug was stored in vials with compromised integrity, labeling, or there is a change in its color (in case of improper storage), it is not suitable for use.
Dissolved vaccine is not subject to storage and should be used immediately after preparation.
Opening the vial and dissolving the lyophilisate should be carried out in compliance with the rules of asepsis.
Structural analogue of Vitagerpavak is Gerpovaks.
Drugs that have similar pharmacological effects are TEOVak and OspaVir drugs.
Terms and conditions of storage
According to the instructions, Vitagerpavak is stored at a temperature of 2-8 ºС for no longer than 2 years from the date of issue.